Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT1 | P04628 | 14/20 | 0.62 |
| ▸ | TGFBR1 | P36897 | 11/20 | 0.62 |
| ▸ | CLK2 | P49760 | 7/20 | 0.57 |
| ▸ | DYRK1A | Q13627 | 7/20 | 0.57 |
| ▸ | CLK3 | P49761 | 6/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17568557 | 0.99 | WNT1 (0.61) | WNT1TGFBR1CLK2DYRK1ACLK3 | |
| SCHEMBL20453393 | 0.92 | CLK2 (0.61) | WNT1TGFBR1CLK2DYRK1ACLK3 | |
| SCHEMBL17568600 | 0.92 | WNT1 (0.66) | WNT1TGFBR1CLK2DYRK1ACLK3 | |
| SCHEMBL17568578 | 0.91 | WNT1 (0.67) | WNT1TGFBR1CLK2DYRK1ACLK3 | |
| SCHEMBL17568625 | 0.91 | WNT1 (0.67) | WNT1TGFBR1CLK2DYRK1ACLK3 | |
| SCHEMBL20453214 | 0.91 | CLK2 (0.60) | WNT1TGFBR1CLK2DYRK1ACLK3 | |
| SCHEMBL17588743 | 0.91 | CLK2 (0.59) | WNT1TGFBR1CLK2DYRK1ACLK3 | |
| SCHEMBL17568603 | 0.91 | WNT1 (0.65) | WNT1TGFBR1CLK2DYRK1ACLK3 | |
| SCHEMBL17573539 | 0.91 | WNT1 (0.66) | WNT1TGFBR1CLK2DYRK1ACLK3 | |
| SCHEMBL17568565 | 0.91 | WNT1 (0.66) | WNT1TGFBR1CLK2DYRK1ACLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9844536-B2 | 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2017-12-19 | — | — | US | disclosed |
| US-9844536-B2 | 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2017-12-19 | — | — | US | disclosed |
| US-20170267697-A1 | 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2017-09-21 | — | — | US | disclosed |
| US-20170267697-A1 | 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2017-09-21 | — | — | US | disclosed |
| US-9540398-B2 | 3-(1h-imidazo[4,5-C]pyridin-2-yl)-1h-pyrazolo[3,4-C]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2017-01-10 | — | — | US | disclosed |
| US-9540398-B2 | 3-(1h-imidazo[4,5-C]pyridin-2-yl)-1h-pyrazolo[3,4-C]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2017-01-10 | — | — | US | disclosed |
| US-20160068547-A1 | 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2016-03-10 | — | — | US | disclosed |
| US-20160068547-A1 | 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2016-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068547-A1 | 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | WNT1 1/4885TGFBR1 479/4885CLK2 2251/4885 |
| US-20170267697-A1 | 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | WNT1 1/4885TGFBR1 479/4885CLK2 2251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.